Pacira BioSciences Non-GAAP EPS of $0.53 misses by $0.09, revenue of $160.3M beats by $0.88M

• Pacira BioSciences press release (NASDAQ:PCRX): Q1 Non-GAAP EPS of $0.53 misses by $0.09.
• Revenue of $160.3M (+1.5% Y/Y) beats by $0.88M.Net product sales of $130.4 million for EXPAREL, $24.3 million for ZILRETTA, and $4.0 million for iovera

• Financial Guidance

  Pacira reiterated its full-year 2023 financial guidance as follows:

  • EXPAREL net product sales of $570 million to $580 million;
  • ZILRETTA net product sales of $115 million to $125 million;
  • iovera° net product sales of $17 million to $20 million;
  • Non-GAAP Gross margin of 76% to 78%;
  • Non-GAAP R&D expense of $70 million to $80 million;
  • Non-GAAP SG&A expense of $220 million to $230 million; and
  • Stock-based compensation of $51 million to $54 million.